The in vitro susceptibility to tobramycin of 1,466 bacterial isolates, including several genera and strains of common pathogenic gram-negative bacilli and Staphylococcus aureus, was determined by conventional serial dilution methods. Tobramycin exhibited marked in vitro antibacterial activity; almost all of the isolates tested were inhibited by~2.5 ug of the drug/ mI. The antibiotic was used in the treatment of several types of infection in 29 patients with normal renal function. Observations were made on the therapeutic and secondary effects of the drug and on possible toxicity to the eighth cranial nerve. Clinical therapeutic results were satisfactory. The hearing of one patient was impaired, but the relation of this effect to tobramycin therapy is uncertain. Serum levels of the antibiotic were measured in 10 patients to investigate whether the drug accumulated during repeated administration. Mean serum levels of tobramycin I hr after intramuscular injection of 1.0 mg/ kg were between 2.5 and 3.0 ug/ ml on days I, 3, and 6 of therapy. No accumulation of the antibiotic was observed after repeated administration.
Tobramycin is a bactericidal aminoglycoside antibiotic produced by the actinomycete Streptomyces tenebrarius. Grown in proper fermentation medium, this organism produced an antibiotic complex of at least seven factors that is now known as nebramycin [1] . Factor 6, currently known as tobramycin, was found to have the highest specific activity and best spectrum [2] . The antibacterial spectrum of tobramycin is similar to that of gentamicin and includes activity against staphylococci and most gram-negative bacteria; however, its activity against gentamicinsusceptible isolates of Pseudomonas aeruginosa is higher than that of gentamicin [3] [4] [5] [6] . Although there is some degree of cross-resistance between the two antibiotics [7] , some isolates of Pseudomonas that are resistant to gentamicin are highly susceptible to tobramycin [8, 9] . This study was supported by a grant from Eli Lilly and Company, Indianapolis, Indiana.
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The purpose of this work was to investigate the in vitro antibacterial activity of tobramycin against common gram-negative bacteria and Staphylococcus aureus and to conduct a clinical study of therapeutic activity, toxicity, and side effects of and tolerance and blood levels for this aminogl ycoside.
Materials and Methods
In vitro susceptibility tests. The MICs of tobramycin for 1,466 bacterial isolates obtained from hospital patients were determined by serial dilution on agar plates. Petri dishes, measuring 15 X 100 mm and containing 20 ml of MuellerHinton agar (Difco; Detroit, Mich.), pH 7.4, were used.
Solutions of tobramycin sulfate in phosphate buffer (pH 7.4) were prepared from a primary standard provided by Eli Lilly and Company, Indianapolis, Ind. These solutions were mixed with liquid agar at 55 C; the volume of buffer was always limited to < 1.5 ml. The OD of bacterial suspensions of each species was adjusted at 640 nm to provide 2 X 10 6 cfu/rnl. The number of cfu was simultaneously verified by colony counts of appropriate dilutions of overnight cultures with isotonic saline solution (pH 7.0) and incorporation on trypticase soy agar.
Tobramycin agar plates were inoculated with 1 X 10 5 cfu with a device that delivers a 0.05-ml volume. MIC values were determined after incubation for 16 hr at 37 C; growth was considered to be inhibited if colonies could not be detected with a magnifying glass.
Clinical studies. Tobramycin was given to 29 patients (15 males and 14 females aged 15-56 years) who were hospitalized for a variety of infectious diseases due to identified pathogens that were inhibited in vitro by~2.5 ug of the drug/rnl in tube-dilution susceptibility tests. Only patients with normal renal function (normal values for blood urea nitrogen and serum creatinine) were treated. Observations were made on the therapeutic efficacy, tolerance, and toxicity of tobramycin.
The following diagnoses were made for the 29 patients (table 1) . Two patients had acute pyelonephritis with significant bacteriuria ( No patient received any antimicrobial agent other than tobramycin during the trial. Dosages of tobramycin were 1 mg/kg per day in one patient (no. 1; table 1) 2 mg/kg per day in four patients (no. 3, 6, 8, and 16), and 3 mg/kg per day in the remaining 24 patients. Tobramycin was given im in three equal, divided doses daily. Fifteen patients were treated for 10 days. Periods of treatment were shorter (seven to nine days) in the event of cure or failure; therapy was prolonged ( 11-17 days) in cases of clinical improvement without cure after 10 days.
Serum levels of tobramycin were studied in 10 patients who received 3 mg/kg per day. Blood samples were obtained before treatment and 1 and 8 hr after the morning dose (1 rug/kg) on days 1, 3, and 6 of therapy. Each serum sample was separated into four aliquots and frozen at -20 C. Serum levels of the drug were determined by a pour-plate method with use of a 12-ml base of antibiotic medium no. 2 (Difco; pH 8.0) and a second 4-ml layer of the same medium inoculated with a 0.05 % suspension of spores of Bacillius subtilis (American Type Culture Collection [ATCC] no. 6633, Rockville, Md.). Filter paper disks (one-half inch; no. 740-E; S & SIne., Keene, New Hampshire) were impregnated with 0.08 ml of appropriate dilutions of tobramycin or of test serum. Several standard curves were made with dilutions of tobramycin sulfate (standard salt) in pooled normal human serum without activity against B. subtilis. A curve including concentrations of 12, 6, 3, 1.5, and 0.75 !-!g/ml was the most appropriate for use in measuring tobramycin concentrations in undiluted sera. The point representing 3 ug/rnl was the reference point of the system. The regression line was drawn according to standard calculations.
Patients were examined daily for side effects or toxic reactions, and the following determinations were made before and after therapy: complete blood count, differential blood count, platelet count, urinalysis, blood urea nitrogen, serum creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase (SGOT), and alanine aminotransferase (SGPT). Bacteriologic cultures for determination of susceptibility to tobramycin were obtained before, during, and after tobramycin therapy. Audiometry and caloric vestibular stimulation tests were also performed before, during, and after therapy, whenever possible.
Results were evaluated on clinical and bacteriologic grounds. Clinically three types of response were considered: cure, when signs of symptoms of the infection disappeared entirely; improvement, when only some of the signs and symptoms disappeared or decreased; and failure, when the clinical picture remained unmodified or worsened. Bacteriologically, five possibilities were considered: (1) clearing or elimination of the pathogen; (2) marked reduction of the pathogen; (3) persistence of the pathogen; (4) appearance of a new pathogen; and (5) results that could not be evaluated.
Results
The cumulative percentage of isolates inhibited by the indicated concentrations of tobramycin are shown in table 2. Therapeutic results are Escdrzaga et al. shown in table 1. Clinical cure was observed in 20 patients, improvement in three, and failure in six. The pathogen was eliminated in 14 cases, and it persisted in eight patients. A new pathogen was isolated during or at the end of treatment in three patients, and the bacteriologic response could not be evaluated in three. In four patients, final bacteriologic studies were not available.
Cures included the two patients with acute pyelonephritis, five with soft tissue infections, four with genitourinary infections, eight with typhoid fever, and one of the five patients with peritonitis.
Two patients with peritonitis and one with otitis improved, r.nd failure occurred in the remaining two patients with peritonitis and in all four patients with chronic osteomyelitis.
The antibiotic was well tolerated. Patients did not complain of pain on injection, and no inflammation was observed at the injection site. There were no manifestations of hypersensitivity, and laboratory determinations indicated no abnormalities attributable to tobramycin. Data are given as cumulative percentages of isolates inhibited by various concentrations of tobramycin.
* One strain of each of these organisms was resistant to even 50 Ilg of tobramycin/ml.
In one patient audiometry after therapy revealed a loss of 10-20 decibels at 6,000 cycles. A relation between this observation and tobramycin therapy could not be established with certainty. We feel that aminoglycoside ototoxicity was not evident in this series.
Serum levels of tobramycin are shown in table 3. Mean serum levels 1 hr after im injection of 1 mg/kg were 2.42 ug/rnl on the first day of therapy, 2.65 ug/rnl on the third day, and 2.99 ug/rnl on the sixth day. The differences between the means were not significant as analyzed by Student's t-test (P > 0.05).
Discussion
All tested isolates of Enterobacter, Citrobacter [reundii, the Bethesda-Ballerup group of Citrobacter, P. aeruginosa, and Salmonella were susceptible in vitro when a concentration of 2.5 p.g of tobramycin/ml was used to separate susceptible from resistant organisms. In addition, >90 % of tested isolates of Alcaligenes faecalis, E. coli, Hajnia, Klebsiella, Proteus, and S. aureus were susceptible by that criteria. It was noteworthy that 25 % of the isolates of enteropathogenic E. coli were resistant to 2.5 ug/rnl, although only 3.6% were resistant to 5 ug/rnl and all were inhibited by 10 ug/rnl.
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Therapeutic results were in agreement with these bacteriologic data, and efficacy was shown in those situations fulfilling minimal requirements for proper antibiotic therapy. In most clinically cured patients, disappearance of the pathogen was documented. In this regard, we chose to classify as bacteriologically nonevaluable three patients with typhoid fever (cases no. 21, 24, and 25; table 1) in whom S. typhi was isolated from bone marrow or feces after treatment, although their clinical course was entirely satisfactory and without relapse. This finding is common in typhoid fever. Therapeutic failures occurred with infections inherently difficult to resolve, such as peritonitis and osteomyelitis, and in which assistance of other methods is mandatory.
The data presented in this paper suggest that because of its antibacterial activity, patient tolerance, serum levels, and therapeutic efficacy, tobramycin is a useful agent for the treatment of infectious diseases, including severe ones, due to susceptible organisms.
It is recommended that, as in use of other aminoglycoside antibiotics, consideration be given to possible toxic effects on the eighth cranial nerve when tobramycin is used. A definite diagnosis and information on renal function of the patient should be required before the drug is administered, and renal function should be monitored during treatment. 
